Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo
- PMID: 22923988
- PMCID: PMC3423151
- DOI: 10.2147/IJN.S32817
Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo
Abstract
Background and methods: Paclitaxel, a widely used antitumor agent, has limited clinical application due to its hydrophobicity and systemic toxicity. To achieve sustained and targeted delivery of paclitaxel to tumor sites, liposomes composed of egg phosphatidylcholine, cholesterol, and distearolyphosphatidyl ethanolamine-N-poly(ethylene glycol) (PEG(2000)) were prepared by a lipid film method. In addition, the liposomes also contained truncated fibroblast growth factor fragment-PEG-cholesterol as a ligand targeting the tumor marker fibroblast growth factor receptor. Physicochemical characteristics, such as particle size, zeta potential, entrapment efficiency, and release profiles were investigated. Pharmacokinetics and biodistribution were evaluated in C57BL/6 J mice bearing B16 melanoma after intravenous injection of paclitaxel formulated in Cremophor EL (free paclitaxel), conventional liposomes (CL-PTX), or in targeted PEGylated liposomes (TL-PTX).
Results: Compared with CL-PTX and free paclitaxel, TL-PTX prolonged the half-life of paclitaxel by 2.01-fold and 3.40-fold, respectively, in plasma and improved the AUC(0→t) values of paclitaxel by 1.56-fold and 2.31-fold, respectively, in blood. Biodistribution studies showed high accumulation of TL-PTX in tumor tissue and organs containing the mononuclear phagocyte system (liver and spleen), but a considerable decrease in other organs (heart, lung, and kidney) compared with CL-PTX and free paclitaxel.
Conclusion: The truncated fibroblast growth factor fragment-conjugated PEGylated liposome has promising potential as a long-circulating and tumor-targeting carrier system.
Keywords: liposomes; paclitaxel; poly(ethylene glycol); targeted drug delivery; truncated fibroblast growth factor fragment.
Figures






Similar articles
-
Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution.Artif Cells Nanomed Biotechnol. 2016;44(1):350-5. doi: 10.3109/21691401.2014.951722. Epub 2014 Aug 27. Artif Cells Nanomed Biotechnol. 2016. PMID: 25162671
-
Truncated bFGF-mediated cationic liposomal paclitaxel for tumor-targeted drug delivery: improved pharmacokinetics and biodistribution in tumor-bearing mice.J Pharm Sci. 2011 Mar;100(3):1196-205. doi: 10.1002/jps.22348. Epub 2010 Sep 21. J Pharm Sci. 2011. PMID: 20860011
-
Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.J Control Release. 2010 Jul 1;145(1):17-25. doi: 10.1016/j.jconrel.2010.03.007. Epub 2010 Mar 20. J Control Release. 2010. PMID: 20307599
-
Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes.J Control Release. 2000 Jan 3;63(1-2):19-30. doi: 10.1016/s0168-3659(99)00166-2. J Control Release. 2000. PMID: 10640577
-
Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.Int J Nanomedicine. 2015 Mar 5;10:1791-804. doi: 10.2147/IJN.S75186. eCollection 2015. Int J Nanomedicine. 2015. PMID: 25784805 Free PMC article.
Cited by
-
Canonical and non-canonical barriers facing antimiR cancer therapeutics.Curr Med Chem. 2013;20(29):3582-93. doi: 10.2174/0929867311320290004. Curr Med Chem. 2013. PMID: 23745563 Free PMC article. Review.
-
NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma.Front Oncol. 2021 Oct 12;11:754541. doi: 10.3389/fonc.2021.754541. eCollection 2021. Front Oncol. 2021. PMID: 34712615 Free PMC article. Review.
-
Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.Int J Nanomedicine. 2015 Aug 12;10:5123-37. doi: 10.2147/IJN.S87011. eCollection 2015. Int J Nanomedicine. 2015. PMID: 26316745 Free PMC article.
-
Nanoparticle-based targeted gene therapy for lung cancer.Am J Cancer Res. 2016 May 1;6(5):1118-34. eCollection 2016. Am J Cancer Res. 2016. PMID: 27294004 Free PMC article.
-
In vitro and in vivo antitumor effects of lupeol-loaded galactosylated liposomes.Drug Deliv. 2021 Dec;28(1):709-718. doi: 10.1080/10717544.2021.1905749. Drug Deliv. 2021. PMID: 33825591 Free PMC article.
References
-
- Chervinsky D, Brecher M, Hoelcle M. Cremophor-EL enhances Taxol efficacy in a multi-drug resistant C1300 neuroblastoma cell line. Anticancer Res. 1993;13:93–96. - PubMed
-
- Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D. Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst. 1993;85:1685–1690. - PubMed
-
- Fjällskog ML, Frii L, Bergh J. Is Cremophor EL, solvent for paclitaxel, cytotoxic? Lancet. 1993;342:873. - PubMed
-
- Rowinsky E, Eisenhauer E, Chaudhry V, Arbuck S, Donehower R. Clinical toxicities encountered with paclitaxel (Taxol) Semin Oncol. 1993;20(4 Suppl 3):1–15. - PubMed
-
- Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother. 1994;28(5):S11–14. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources